On May 21, 2025 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that the Phase III TALENTACE study, evaluating the efficacy and safety of Tecentriq (atezolizumab), Avastin (bevacizumab), and on-demand transarterial chemoembolization (TACE) in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic treatment, met its primary endpoint with positive results (Press release, Chugai, MAY 21, 2025, View Source [SID1234653268]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of TACE-progression-free survival (TACE PFS*), and the other primary endpoint of overall survival (OS) is immature at the prespecified first interim analysis. Meanwhile, a clinically meaningful PFS by RECIST v1.1** was also observed. Detailed findings from this study will be presented at an upcoming academic congress.
*TACE PFS: Defined as the time from randomization to untreatable progression or TACE failure/refractoriness or death by any cause as determined by the investigator, and OS (overall survival), defined as time from randomization to death from any cause.
**RECIST v1.1: Response Evaluation Criteria in Solid Tumors guideline
Initiated in collaboration in China and Japan, the TALENTACE study aimed to assess whether combining Tecentriq and Avastin with TACE could improve outcomes for patients with unresectable HCC. This marks the Phase III study in Asia showing a TACE PFS benefit from cancer immunotherapy and target therapy in combination with TACE for unresectable HCC. The safety profiles of atezolizumab and bevacizumab were consistent with the well-established safety profile of each therapeutic agent and the underlying disease.
About the TALENTACE Study
TALENTACE study is a phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with Tecentriq + Avastin or on-demand transarterial chemoembolization (TACE) alone in patients with unresectable hepatocellular carcinoma who have not received prior systemic treatment. The TALENTACE study enrolled 342 patients in China and Japan who were randomized on a 1:1 ratio to receive TACE + Tecentriq/Avastin or TACE alone. TACE was performed on-demand. The co-primary endpoints are TACE PFS (TACE progression-free survival) and OS (overall survival). Secondary endpoints include PFS by RECIST v1.1 and others.
About Liver cancer
Liver cancer is the third leading cause of cancer-related death globally and one of the few cancers with rising mortality rates.1,2 More than 500,000 people are diagnosed with liver cancer every year, translating to one person being diagnosed every 50 seconds.1 Despite advances in treatment, only one in five people with liver cancer are alive five years post-diagnosis, and survival rates for advanced disease are even lower.